FarkasJ. PulmCrit- Alpha-2 agonists: Clonidine, guanfacine, lofexidine, and KetaDex. EMCrit Project; December 3, 2018. Available from: https://emcrit.org/pulmcrit/ketadex/ [Last accessed: August29, 2023].
4.
CarrA, FergusonM. What is the evidence to support clonidine as an adjuvant analgesic? Pract Pain Manag, 2019; 19(5).
5.
NeilMJ. Clonidine: Clinical pharmacology and therapeutic use in pain management. Curr Clin Pharmacol, 2011; 6(4):280–287.
6.
KumarA, MaitraS, KhannaP, et al.Clonidine for management of chronic pain: A brief review of the current evidence. Saudi J Anaesth, 2014; 8(1):92–96.
7.
GoldenbergG, BharathanT, ShifrinI. Transdermal clonidine in patients with swallowing dysfunction. J Palliat Med, 2014; 17(9):1042–1044.
8.
The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med, 2020; 14(2S):1–91.
9.
The ASAM clinical practice guideline on alcohol withdrawal management. J Addict Med, 2020; 14(3S Suppl 1):1–72.
10.
YeL, LippmannS. Reduction of anxiety after treatment with transdermal clonidine. Am J Health Syst Pharm, 2018; 75(11):742–744.
11.
BergendahlH, LönnqvistPA, EksborgS. Clonidine in paediatric anaesthesia: Review of the literature and comparison with benzodiazepines for premedication. Acta Anaesthesiol Scand, 2006; 50(2):135–143.
12.
GagnonDJ, FontaineGV, RikerRR, et al.Repurposing valproate, enteral clonidine, and phenobarbital for comfort in adult ICU patients: A literature review with practical considerations. Pharmacotherapy, 2017; 37(10):1309–1321.
13.
ManoA, MurataT, DateK, et al.Dexmedetomidine for dyspnoea. BMJ Support Palliat Care, 2020; 13(e1):e84–e85.
14.
LiN, CuiM, WangY. Effect of dexmedetomidine for palliative sedation for refractory dyspnoea in patients with terminal-stage cancer. Cancer Manag Res, 2023; 15:291–299.
15.
GaertnerJ, Fusi-SchmidhauserT. Dexmedetomidine: A magic bullet on its way into palliative care-a narrative review and practice recommendations. Ann Palliat Med, 2022; 11(4):1491–1504.
16.
JiangS, HernandezM, BurkeH, et al.A retrospective analysis of guanfacine for the pharmacological management of delirium. Cureus, 2023; 15(1):e33393.
17.
JiangS, CzumaR, Cohen-OramA, et al.Guanfacine for hyperactive delirium: A case series. J Acad Consult Liaison Psychiatry, 2021; 62(1):83–88.
18.
FettersMB, DiepC, RanR, et al.Effect of enteral guanfacine on dexmedetomidine use in the ICU. Crit Care Explor, 2022; 4(11):e0785.
19.
SrourH, PandyaK, FlanneryA, et al.Enteral guanfacine to treat severe anxiety and agitation complicating critical care after cardiac surgery. Semin Cardiothorac Vasc Anesth, 2018; 22(4):403–406.
20.
SmithHS, BartonAE. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population. Am J Hosp Palliat Care, 2000; 17(1):50–58.
21.
NairA, RangaiahM, BorkarN. Efficacy and safety of oral tizanidine premedication as pre-emptive analgesia in adult patients undergoing elective surgeries—A systematic review. Saudi J Anaesth, 2023; 17(2):214–222.
22.
DoughtyB, MorgensonD, BrooksT. Lofexidine: A newly FDA-approved, nonopioid treatment for opioid withdrawal. Ann Pharmacother, 2019; 53(7):746–753.
